Regenxbio IncNASDAQ:RGNX
- LAST PRICE9.5600
- TODAY'S CHANGE (%)-0.5900 (-5.8128%)
- Bid / Lots9.2300/ 10
- Ask / Lots9.8500/ 2
- Open / Previous Close9.9200 / 10.1500
- Day Range
- 52 Week Range
- Volume2,029,754
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 24171 | 9.7535 |
| 09:33 ET | 7588 | 9.84 |
| 09:35 ET | 5750 | 9.735 |
| 09:37 ET | 3203 | 9.59 |
| 09:39 ET | 1141 | 9.59 |
| 09:42 ET | 7721 | 9.55 |
| 09:44 ET | 45956 | 9.2644 |
| 09:46 ET | 6614 | 9.2601 |
| 09:48 ET | 17969 | 9.2502 |
| 09:50 ET | 36079 | 9.1387 |
| 09:51 ET | 10276 | 9.14 |
| 09:53 ET | 18389 | 9.17 |
| 09:55 ET | 8950 | 9.175 |
| 09:57 ET | 2534 | 9.22 |
| 10:00 ET | 5708 | 9.16 |
| 10:02 ET | 17435 | 9.12 |
| 10:04 ET | 5798 | 9.17 |
| 10:06 ET | 990 | 9.135 |
| 10:08 ET | 11785 | 9.15 |
| 10:09 ET | 1900 | 9.12 |
| 10:11 ET | 4740 | 9.2038 |
| 10:13 ET | 2000 | 9.22 |
| 10:15 ET | 3625 | 9.27 |
| 10:18 ET | 4071 | 9.33 |
| 10:20 ET | 1816 | 9.27 |
| 10:22 ET | 2231 | 9.26 |
| 10:24 ET | 8412 | 9.28 |
| 10:26 ET | 4964 | 9.29 |
| 10:27 ET | 2894 | 9.26 |
| 10:29 ET | 7651 | 9.215 |
| 10:31 ET | 2636 | 9.26 |
| 10:33 ET | 491 | 9.25 |
| 10:36 ET | 4589 | 9.3301 |
| 10:38 ET | 3600 | 9.4 |
| 10:40 ET | 2745 | 9.34 |
| 10:42 ET | 1852 | 9.2899 |
| 10:44 ET | 3626 | 9.26 |
| 10:45 ET | 1600 | 9.28 |
| 10:47 ET | 1425 | 9.21 |
| 10:49 ET | 2642 | 9.2201 |
| 10:51 ET | 1000 | 9.2325 |
| 10:54 ET | 13571 | 9.06 |
| 10:56 ET | 19367 | 9.025 |
| 10:58 ET | 14912 | 9 |
| 11:00 ET | 5303 | 9.0128 |
| 11:02 ET | 10863 | 9.07 |
| 11:03 ET | 8968 | 9.02 |
| 11:05 ET | 7673 | 9.05 |
| 11:07 ET | 7906 | 9.02 |
| 11:09 ET | 14479 | 9.0167 |
| 11:12 ET | 659 | 9.025 |
| 11:14 ET | 5419 | 9.05 |
| 11:16 ET | 4391 | 8.9999 |
| 11:18 ET | 2239 | 9.0167 |
| 11:20 ET | 3516 | 9.01 |
| 11:21 ET | 17162 | 9.02 |
| 11:23 ET | 6053 | 8.97 |
| 11:25 ET | 18953 | 8.9 |
| 11:27 ET | 9403 | 8.88 |
| 11:30 ET | 2784 | 8.9 |
| 11:32 ET | 4999 | 8.9268 |
| 11:34 ET | 9589 | 8.99 |
| 11:36 ET | 2213 | 8.98 |
| 11:38 ET | 11959 | 9.0875 |
| 11:39 ET | 6253 | 9.125 |
| 11:41 ET | 6200 | 9.1 |
| 11:43 ET | 4200 | 9.15 |
| 11:45 ET | 3955 | 9.08 |
| 11:48 ET | 11397 | 9.09 |
| 11:50 ET | 1996 | 9.0733 |
| 11:52 ET | 2918 | 9.04 |
| 11:54 ET | 5700 | 9.12 |
| 11:56 ET | 13079 | 9.2167 |
| 11:57 ET | 7038 | 9.2297 |
| 11:59 ET | 1600 | 9.25 |
| 12:01 ET | 5331 | 9.135 |
| 12:03 ET | 2000 | 9.1198 |
| 12:06 ET | 5738 | 9.15 |
| 12:08 ET | 3925 | 9.1837 |
| 12:10 ET | 700 | 9.22 |
| 12:12 ET | 2233 | 9.25 |
| 12:14 ET | 4307 | 9.3 |
| 12:15 ET | 1926 | 9.26 |
| 12:17 ET | 300 | 9.244255 |
| 12:19 ET | 200 | 9.2401 |
| 12:21 ET | 300 | 9.265 |
| 12:24 ET | 1842 | 9.215 |
| 12:26 ET | 1100 | 9.2 |
| 12:28 ET | 2750 | 9.19 |
| 12:30 ET | 2282 | 9.17 |
| 12:32 ET | 302 | 9.16 |
| 12:33 ET | 5065 | 9.23 |
| 12:35 ET | 1950 | 9.2 |
| 12:37 ET | 749 | 9.1873 |
| 12:39 ET | 1575 | 9.12 |
| 12:42 ET | 4408 | 9.105 |
| 12:44 ET | 3308 | 9.05 |
| 12:46 ET | 2174 | 9.04 |
| 12:48 ET | 4757 | 9.13 |
| 12:50 ET | 3575 | 9.12 |
| 12:51 ET | 4900 | 9.1 |
| 12:53 ET | 3646 | 9.18 |
| 12:55 ET | 1244 | 9.18 |
| 12:57 ET | 2075 | 9.14 |
| 01:00 ET | 500 | 9.14 |
| 01:02 ET | 4399 | 9.11 |
| 01:04 ET | 3109 | 9.1 |
| 01:06 ET | 11641 | 9.1 |
| 01:08 ET | 1519 | 9.1 |
| 01:09 ET | 2035 | 9.1 |
| 01:11 ET | 700 | 9.1001 |
| 01:13 ET | 6435 | 9.1084 |
| 01:15 ET | 3915 | 9.1 |
| 01:18 ET | 2226 | 9.105 |
| 01:20 ET | 2430 | 9.11 |
| 01:22 ET | 3914 | 9.1 |
| 01:24 ET | 2933 | 9.101 |
| 01:26 ET | 9548 | 9.1 |
| 01:27 ET | 8563 | 9.11 |
| 01:29 ET | 22798 | 9.11 |
| 01:31 ET | 2398 | 9.11 |
| 01:33 ET | 4098 | 9.1 |
| 01:36 ET | 6748 | 9.118 |
| 01:38 ET | 5638 | 9.11 |
| 01:40 ET | 7564 | 9.12 |
| 01:42 ET | 1705 | 9.17 |
| 01:44 ET | 1899 | 9.135 |
| 01:45 ET | 1200 | 9.1596 |
| 01:47 ET | 5334 | 9.15 |
| 01:49 ET | 1250 | 9.15 |
| 01:51 ET | 4167 | 9.13 |
| 01:54 ET | 1100 | 9.13 |
| 01:56 ET | 5515 | 9.115 |
| 01:58 ET | 4660 | 9.115 |
| 02:00 ET | 4200 | 9.1 |
| 02:02 ET | 5514 | 9.105 |
| 02:03 ET | 3973 | 9.1 |
| 02:05 ET | 2450 | 9.1096 |
| 02:07 ET | 7323 | 9.1 |
| 02:09 ET | 6809 | 9.1 |
| 02:12 ET | 9210 | 9.1 |
| 02:14 ET | 3461 | 9.101 |
| 02:16 ET | 11254 | 9.1 |
| 02:18 ET | 41868 | 9.13 |
| 02:20 ET | 1100 | 9.1 |
| 02:21 ET | 6181 | 9.12 |
| 02:23 ET | 203 | 9.11 |
| 02:25 ET | 2183 | 9.1 |
| 02:27 ET | 2752 | 9.105 |
| 02:30 ET | 800 | 9.1088 |
| 02:32 ET | 1700 | 9.1 |
| 02:34 ET | 32109 | 9.1 |
| 02:36 ET | 1587 | 9.02 |
| 02:38 ET | 2896 | 9.03 |
| 02:39 ET | 1755 | 9.02 |
| 02:41 ET | 1283 | 9.025 |
| 02:43 ET | 5148 | 9.07 |
| 02:45 ET | 676 | 9.06 |
| 02:48 ET | 6324 | 9.08 |
| 02:50 ET | 100 | 9.07 |
| 02:52 ET | 11331 | 9.115 |
| 02:54 ET | 12441 | 9.11 |
| 02:56 ET | 1118 | 9.12 |
| 02:57 ET | 4493 | 9.16 |
| 02:59 ET | 2100 | 9.16 |
| 03:01 ET | 7884 | 9.19 |
| 03:03 ET | 2259 | 9.2 |
| 03:06 ET | 78995 | 9.21 |
| 03:08 ET | 762 | 9.2 |
| 03:10 ET | 5294 | 9.19 |
| 03:12 ET | 2695 | 9.21 |
| 03:14 ET | 3800 | 9.27 |
| 03:15 ET | 6413 | 9.24 |
| 03:17 ET | 1500 | 9.255 |
| 03:19 ET | 1975 | 9.255 |
| 03:21 ET | 1903 | 9.265 |
| 03:24 ET | 300 | 9.27 |
| 03:26 ET | 9101 | 9.27 |
| 03:28 ET | 5048 | 9.32 |
| 03:30 ET | 9665 | 9.41 |
| 03:32 ET | 4958 | 9.415 |
| 03:33 ET | 3371 | 9.375 |
| 03:35 ET | 8853 | 9.385 |
| 03:37 ET | 5940 | 9.4001 |
| 03:39 ET | 2912 | 9.415 |
| 03:42 ET | 10765 | 9.36 |
| 03:44 ET | 8812 | 9.33 |
| 03:46 ET | 18090 | 9.32 |
| 03:48 ET | 11989 | 9.29 |
| 03:50 ET | 6819 | 9.275 |
| 03:51 ET | 16671 | 9.265 |
| 03:53 ET | 26380 | 9.32 |
| 03:55 ET | 29872 | 9.39 |
| 03:57 ET | 15117 | 9.4 |
| 04:00 ET | 285771 | 9.56 |
Nov 18, 2024
DJ Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion, from 9:09AM ET on Monday Nov 18, 2024 by Dow Jones
9:09AM ET on Monday Nov 18, 2024 by Dow JonesREGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE(R) TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA, from 7:05AM ET on Monday Nov 18, 2024 by Dow Jones
7:05AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 15, 2024
DJ REGENXBIO Coverage Assumed by Morgan Stanley at Overweight, from 7:14AM ET on Friday Nov 15, 2024 by Dow Jones
7:14AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE(R) Trial of RGX-202, from 7:05AM ET on Thursday Nov 14, 2024 by Dow Jones
7:05AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
DJ REGENXBIO Is Maintained at Buy by HC Wainwright & Co., from 3:43PM ET on Thursday Nov 07, 2024 by Dow Jones
3:43PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 502.9M | -1.9x | --- |
Grail Inc | 470.4M | 0.0x | --- |
Y-mAbs Therapeutics Inc | 477.8M | -20.1x | --- |
Urogen Pharma Ltd | 465.9M | -3.6x | --- |
Chromadex Corp | 555.3M | 397.3x | --- |
Alector Inc | 368.2M | -2.3x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Kenneth Mills
- President, Chief Executive Officer, Director
- Curran Simpson
- Chief Financial Officer, Executive Vice President, Principal Accounting Officer
- Mitchell Chan
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
- Executive Vice President, Chief Legal Officer
- Patrick Christmas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $502.9M |
|---|---|
Revenue (TTM) | $84.3M |
Shares Outstanding | 49.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-5.03 |
Book Value | $7.08 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -291.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
